Anaplastic thyroid cancer: multimodal treatment results

30 Jul 2014
Zaki Antonio Taissoun Aslan, Martín Granados-García, Kuauhyama Luna-Ortiz, Francisco Javier Guerrero-Huerta, Antonio Gómez-Pedraza, Silvio A Ñamendys-Silva, Abelardo Meneses-García, Juliana María Ordoñez-Mosquera

Background: Anaplastic thyroid cancer is a rare and lethal disease. It accounts for 1–2% of thyroid malignancies, but specific mortality is higher than 90%. It is an aggressive locoregional disease with a high metastatic capacity. There is no agreement with regards to the best treatment. We analysed the results of treatment in a mestizo population treated in the National Cancer Institute (Mexico).

Methods: We reviewed 1,581 files of thyroid carcinomas; of these, 29 (1.83%) had anaplastic thyroid carcinoma. Demographic variables, clinical manifestations, tumour characteristics, and treatments were analysed.

Results: The median age was 64.5 ± 13.2 years. Females were more affected (female/male ratio: 2.6:1); 21 cases occurred in women (72.4%), and eight in males (27.6%). The most common manifestations were neck enlargement (93.10%) and hoarseness (71.31%). The median tumour size was 8 cm (range: 4–20 cm). The percentage of cases which presented in clinical stage IVA was 10.3%, with 62.1% presenting in clinical stage IVb and 27.6% presenting in clinical stage VIc. Complete resection (R0) (p = 0.05), radiation doses of higher than 33.1 Gy (p = 0.04), and multimodal therapy were associated with better survival. Surgery plus radiotherapy with or without systemic treatment (p = 0.006). The median overall survival was 119 days (IC 95%, 36.3–201.6). Six-month, one-year and two-year survival was 37.9%, 21% and 13%, respectively.

Conclusion: Complete surgical resection is associated with better survival but is very difficult to achieve due to aggressive biological behaviour. Multimodal therapy is associated with better survival and a better quality of life. There is a need for more effective systemic treatments as extensive surgical resections have little overall benefit in highly invasive and metastatic disease.

Related Articles

Amit Joshi, Vijay Maruti Patil, Vanita Noronha, Atanu Bhattacharjee, Nandini Menon, Amit Kumar, Parmanand Jain, Sadaf Mukadam, Avadhoot Shrinivas, Anjali Punia, Anuja Abhyankar, Amit Agarwal, Satvik Khaddar, Anu Rajpurohit, Kanteti Aditya Pavan Kumar, Rahul Ravind, Kishore Das, Vikas Talreja, Sachin Dhumal, Kumar Prabhash
Jemma Arakelyan, Alisa Movsisyan, Lilit Sargsyan, Armine Chopikyan, Diana Andreasyan, Arevik Torosyan, Ruzanna Papyan, Hovhannes Vardevanyan, Samvel Bardakhchyan, Artashes Tadevosyan, Gevorg Tamamyan, Armen Tananyan, Samvel Danielyan, Dickran Kazandjian
Percy Torres-Quispe, Lissett Jeanette Fernández-Rodríguez, Yaowen Zhang, Angeles Rovirosa-Casino
Eduardo Payet, Joan Perez, Gustavo Sarria, Silvia Neciosup, Francisco Berrospi, Sheila Vilchez, Jorge Dunstan, Ronald Perez, Mauricio Vassallo, Santiago Salgado, Nanto Caparachín, Joseph A Pinto, Alexis Holguin